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Objectives: To present the validation and clinical application of a LC–MS/MS method for the quantiﬁcation of
lamivudine (3TC), emtricitabine (FTC) and tenofovir (TFV) in dried blood spots (DBS) and dried breast milk
spots (DBMS).
Methods: DBS and DBMS were prepared from 50 and 30 μL of drug-spiked whole blood and human breast milk,
respectively. Following extraction with acetonitrile and water, chromatographic separation utilised a Synergi
polar column with a gradient mobile phase program consisting of 0.1% formic acid in water and 0.1% formic
acid in acetonitrile. Detection and quantiﬁcation was performed using a TSQ Quantum Ultra triple quadrupole
mass spectrometer. The analytical method was used to evaluate NRTI drug levels in HIV-positive nursing mo-
thers-infant pairs.
Results: The assay was validated over the concentration range of 16.6–5000 ng/mL for 3TC, FTC and TFV in DBS
and DBMS except for TFV in DBMS where linearity was established from 4.2–1250 ng/mL. Intra and inter-day
precision (%CV) ranged from 3.5–8.7 and accuracy was within 15% for all analytes in both matrices. The mean
recovery in DBS was> 61% and in DBMS>43% for all three analytes. Matrix eﬀect was insigniﬁcant.
Median AUC0-8 values in maternal DBS and DBMS, respectively, were 4683 (4165–6057) and 6050
(5217–6417) ng h/mL for 3TC, 3312 (2259–4312) and 4853 (4124–6691) ng h/mL for FTC and 1559
(930–1915) and 56 (45–80) ng h/mL for TFV. 3TC and FTC were quantiﬁable (> 16.6 ng/mL) in DBS from 2/6
and 1/6 infants respectively whereas TFV was undetectable in all infants.
Conclusions: DBS and DBMS sampling for bioanalysis of 3TC, FTC and TFV is straightforward, robust, accurate
and precise, and ideal for use in low-resource settings.
1. Introduction
It is internationally recommended that HIV-positive women receive
triple antiretroviral therapy (ART) throughout pregnancy until the end
of breastfeeding or for life irrespective of clinical disease stage or CD4
count [1]. As breastfeeding remains the only acceptable, feasible, af-
fordable, sustainable and safe infant feeding option in many parts of the
world [2], the number of infants exposed to antiretroviral drugs
through pregnancy and breastfeeding will continue to increase.
First-line ART comprises efavirenz (EFV), tenofovir diproxil fuma-
rate (TDF) and either lamivudine (3TC) or emtricitabine (FTC) used
preferably as a ﬁxed-dose combination. It is important to understand
the breast milk transfer of these drugs since low infant levels predispose
to HIV-drug resistance should HIV transmission occur [3,4], and there
is conﬂicting data regarding the eﬀects of tenofovir (TFV) on devel-
oping bone [5]. The pharmacokinetic proﬁles in paired maternal and
infant plasma (calculated from dried blood spots [DBS]) and breast milk
(BM) have been reported for EFV [6] and 3TC [7], but only three stu-
dies have sought to measure TFV [8–10] and a single study FTC in the
BM of HIV-positive mothers [8], and these did not present intensive
pharmacokinetic proﬁles and paired mother and infant data.
Furthermore, a systematic review of antiretroviral measurement in
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BM noted marked methodological diﬀerences with regard to the col-
lection and storage of samples, the matrix used to prepare the standards
and quality controls, the fraction of milk analysed, the extraction
method and the type of internal standard used [11]. We have recently
developed and validated dried blood spot (DBS) and dried breast milk
spot (DBMS) methodology for EFV [12] and nevirapine (NVP) [13]. In
addition to quantifying drugs in whole BM, these techniques have the
advantage of being suitable for collection and storage in low resource
settings. We now report the DBS and DBMS LC–MS/MS method for
accurate simultaneous quantitation of TFV, 3TC and FTC, with appli-
cation of the method in breastfeeding mother-infant pairs.
2. Materials and methods
Lamivudine (3TC) and internal standard (IS) lamivudine-15N2,13C
(3TC-IS), emtricitabine (FTC) and emtricitabine-13C,15N2 (FTC-IS) and
tenofovir (TFV) were obtained from TRC Canada (North York, Ontario).
LC–MS grade acetonitrile was obtained from Fisher Scientiﬁc
(Loughborough, Leicestershire, UK), methanol from VWR International
(Lutterworth, Leicestershire, UK), formic acid from Sigma-Aldrich
(Gillingham, Dorset, UK) and water was produced from an Elga Option
4 water puriﬁer (Elga LabWater, High Wycombe, Buckinghamshire,
UK) and was further puriﬁed to 18.2 MΩ with a Purelab Classic UVF
(Elga LabWater, High Wycombe, Buckinghamshire, UK). Whatman 903
Protein Saver cards were obtained from Scientiﬁc Laboratory Supplies
(Hessle, East Yorkshire, UK). Blank whole blood was collected into
EDTA tubes from drug-free healthy volunteers and blank BM samples
were obtained from the Wirral Mothers’ Milk Bank, Clatterbridge
Hospital, Wirral, UK; the University of Liverpool Research Ethics
Committee approved these processes.
2.1. LC–MS systems and conditions
The LC–MS system consisted of a Synergi polar-RP column (80A,
150 *2.0 mm and 4 μ; Phenomenex, Macclesﬁeld, UK) with a 2 μm C18
Quest column-saver (Thermo Electron Corporation, Hemel Hempstead,
Hertfordshire, UK) on a HPLC connected to a TSQ Quantum Ultra triple
quadrupole mass spectrometer (Thermo Electron Corporation, Hemel
Hempstead, Hertfordshire, UK) equipped with a heated electrospray
ionisation source (H-ESI). Xcalibur Software and LCquan (version 2.6.1,
Thermo Fisher Scientiﬁc, Hemel Hempstead, UK) were used for method
setup, data acquisition, data processing and reporting.
A solvent gradient programme (ﬂow rate of 400 μL/min) with 0.1%
formic acid in water (mobile phase A) and 0.1% formic acid in acet-
onitrile (mobile phase B) was used for chromatographic separation. The
gradient programme started with 95% mobile phase A, and held for
0.2 min. Mobile phase A was decreased to 70% over 0.5 min. This was
maintained for 3.0 min, followed by column equilibration to the initial
conditions. The total run time was 6.0 min. The Injection volume was
25 μL and the needle was washed twice with 2 mL water: acetonitrile
(95:5) between injections. The MS was operated in positive ionisation
mode to produce characteristic fragmentation patterns. The electro-
spray voltage was set at 4.0 kV, the capillary temperature at 300 °C and
the vaporizer temperature at 350 °C. The sheath and auxiliary gas
pressures were set of 50 and 10 arbitrary units, respectively. Argon was
used as the collision gas at a pressure of 1.5 mTorr. Product ion char-
acterisation and tuning was done by directly infusing 1 μg/mL solutions
of all the three analytes and their internal standards separately into the
MS using a syringe at a ﬂow rate of 5 μL/min. The most sensitive mass
transitions (m/z) were monitored in selective reaction monitoring.
2.2. Stock solutions, calibration standards and quality controls (QC)
3TC and FTC stock solutions were prepared from their respective
reference standards in 100% methanol, and TFV in 100% water to
obtain a ﬁnal concentration of 1 mg/mL and refrigerated at 4 °C until
use. Similarly, 3TC-IS and FTC-IS 1 mg/mL stock solutions were pre-
pared and frozen at −40 °C; working stock solutions of 250 ng/mL
were prepared in methanol-water (50:50 v/v) and refrigerated at 4 °C
prior to use. At the time of validation, the cost to purchase a stable
isotope labelled internal standard for TFV was beyond our budget. 3TC-
IS, FTC-IS and an analog IS (2-Chloroadenosine) were evaluated as
potential IS for TFV in pre-validation experiments. FTC-IS was selected
on the basis of it exhibiting a consistent response. A whole blood
working stock containing all three analytes at 10 μg/mL was prepared,
tumbled for 60 min and used to make nine whole blood standards in the
range of 16.6–5000 ng/mL by serial dilution, including a blank sample
of blood alone. Whole blood low quality control (LQC, 40 ng/mL),
medium quality control (MQC, 400 ng/mL) and high quality control
(HQC, 4000 ng/mL) samples were similarly prepared from a 10 μg/mL
working stock. Working stocks in human breast milk were similarly
prepared, with the diﬀerence that the calibration range for tenofovir
was 4.2–1250 ng/mL with LQC 10 ng/mL, MQC 40 ng/mL and HQC
400 ng/mL respectively due to the lower anticipated concentrations of
this analyte in clinical specimens [9].
2.3. DBS and DBMS standard and QC preparation
DBS standards and QCs were prepared by carefully spotting exactly
50 μL of whole blood standards and QCs on each circle of Whatman 903
Protein Saver Cards. DBMS standards and QCs were similarly prepared
by spotting 30 μL of breast milk standards and QCs. Spotted cards were
left to dry at room temperature overnight and stored with dessicant
sachets in ziplock bags at −80 °C.
2.4. Sample pre-treatment
The entire DBS or DBMS spot was removed using a 12 mm hole
punch and folded into a 7 mL screw cap tube. For DBS, initial extraction
was with 200 μL 0.1% formic acid in water for 5 min prior to the ad-
dition of 3TC-IS and FTC-IS. IS was added to the extraction solvent [14]
since spotting directly onto the card was not feasible for samples col-
lected under ﬁeld conditions. Then 800 μL acetonitrile was added to
each tube and after vortexing, tubes were centrifuged at 4000 rpm for
10 min. 850 μL of each sample was carefully pipetted into a 5 mL tube,
before evaporation to dryness under a stream of nitrogen. Finally,
samples were reconstituted in 100 μL water: acetonitrile (99:1 v/v) and
transferred into autosampler vials.
DBMS samples were extracted with 1 mL of acetonitrile: water
(70:30, v/v) by tumbling for 30 min in the presence of 3TC-IS and FTC-
IS. 800 ul was then transferred to a 5 mL glass tube, before evaporation
to dryness under a stream of nitrogen. Finally, samples were recon-
stituted in 100 μL water: acetonitrile (99:1 v/v) and transferred into
autosampler vials.
2.5. Calibration curves, accuracy and precision
A calibration curve consisting of a zero blank, nine standards in the
range of 16.6–5000 ng/mL (and 4.2–1250 ng/mL in the case of DBMS
for TFV) (n = 2 separate extractions for each level) and QCs (n = 6
separate extractions for each level) were run for each of DBS and DBMS.
Calibration curves were constructed using a linear regression equation
of analyte/IS peak area ratios versus nominal concentrations with a 1/
concentration weighting. Accuracy was deﬁned as percentage deviation
of measured concentration from the nominal value and precision was
deﬁned as the percentage coeﬃcient of variation (%CV). Not less than
75% of all standards and 67% of all QCs (50% at each level) in any
batch were required to have a percentage deviation within±15%.
2.6. Recovery, matrix eﬀect and dilution integrity
The percentage recovery and matrix eﬀect were determined
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quantitatively (in accordance to the recommendations of Matuszewski
et al) by preparing LQC, MQC and HQC samples (n = 6), DBS and
DBMS, as follows: A: pure standard solutions of analytes in mobile
phase, directly injected onto the column; B: blank DBS/DBMS extracts,
spiked with analytes after extraction; C: whole blood and BM samples
spiked with analyte before extraction [15].
The overall recovery (process eﬃciency; PE) was deﬁned as the
ratio of the absolute peak-area response of the analytes in whole blood/
BM spiked with drug prior to extraction (C) to the peak area response of
analytes in an aqueous mobile phase sample (A) (C/A × 100). The
matrix eﬀect (ME) was calculated as the ratio of the peak area response
of analytes spiked into blank DBS/DBMS extracts after extraction (B) to
the peak areas of the analytes in mobile phase (A) (B/A × 100). The
recovery (extraction yield, RE) was derived from the absolute peak-area
response in whole blood and BM samples spiked with analytes prior to
extraction (C), expressed as the percentage of the response of the
Fig. 1. Representative chromatograms at lower and upper limits of quantitation for both DBS and DBMS, together with a representative patient chromatogram.
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equivalent amount of analyte spiked into DBS/DBMS extracts after
extraction (B) (C/B × 100). A %CV of ≤15% across all QC con-
centrations was set as the level of acceptance for both recovery and
matrix eﬀect in line with the FDA method validation guidelines [16].
To investigate dilution integrity for clinical samples with con-
centrations above the reference range, 50 μL of whole blood containing
9000 ng/mL of 3TC, FTC and TFV and 30 μL of breast milk containing
9000 ng/mL of 3TC and FTC and 2000 ng/mL of TFV were spotted onto
each circle of Whatman 903 cards. The samples were dried and ex-
tracted as described previously. The extracts were diluted 2× and 4×
using blank DBS and DBMS spots similarly extracted in the same batch.
The ﬁnal concentrations were then derived by back-calculating with the
appropriate dilution factor.
2.7. Stability and re-injection (inter-day and intra-day) reproducibility
We evaluated the short-term and medium-term stability of 3TC, FTC
and TFV in DBS and DBMS at diﬀerent storage and processing condi-
tions. This was evaluated by storing extracted QC samples at room
temperature and in the autosampler (4 °C) for 24 h. Both inter-day and
intra-day reproducibility were evaluated. For medium and long-term
stability at room temperature (24 °C), DBS and DBMS QC samples were
stored at room temperature for 1 and 6 months (DBS) and 9 months
(DBMS). Our research laboratories in the UK, Nigeria and Uganda were
all temperature controlled, without signiﬁcant ﬂuctuations in ambient
temperature. Drug concentrations in stored samples were read oﬀ a
calibration curve using freshly made standards and QCs. An accepted
validation assay batch (standards and QCs) was re-injected after 24 h in
the autosampler to evaluate re-injection reproducibility. Samples were
considered stable if values were within the acceptance limits of accu-
racy (± 15% of their respective nominal concentration) and precision
(≤15%CV).
2.8. Eﬀect of haematocrit
60 mL whole blood was collected in EDTA and prepared following
the method of Koster et al. [17]. Centrifugation at 15 g for 15 min at
room temperature separated the plasma and red blood cells. Increasing
volumes of plasma were added to whole blood to ‘dilute’ it, providing
decreasing HCT levels of approximately 100%, 80%, 60%, 40%, 20%
and 0% of ‘normal’, respectively. The non-centrifuged whole blood
served as 100% control, the plasma as 0% and a> 100% HCT sample
was produced by adding 500 μL of packed cells to 1 mL of whole blood.
These were then analysed for%HCT levels on a UniCel DxH 800
Workcell auto-analyser (Beckman Coulter Ltd, High Wycombe, United
Kingdom). The blood was then spiked with the three analytes to provide
the LQC, MQC and HQC levels as detailed above (including tumbling
for 60 min) prior to spotting 50 μL of each onto Whatman 903 cards.
These samples were then dried, extracted and analysed. Furthermore,
concentrations of 3TC and TFV were measured in paired plasma and
DBS from 6 nursing mothers in Uganda (Section 2.9), and the re-
lationship between the maternal plasma: DBS ratio and HCT con-
sidered.
2.9. Clinical application
The validated method was applied in two studies to evaluate DBS
and BM pharmacokinetic proﬁles of ARVs in HIV-positive nursing
mothers and their infants.
3TC was measured in Ugandan HIV-positive nursing mothers
(n = 6) receiving regimens containing 150 mg taken every 12 h.
Trough concentrations of TFV were measured in a further 6 nursing
mothers taking EFV-based ART each evening. Patients were recruited at
the Infectious Diseases Institute, Makerere University, Kampala,
Uganda. The study protocol and the material transfer agreement were
approved by the University of Liverpool Research Ethics Committee, UK
and the Joint Clinical Research Centre IRB, Uganda and the Uganda
National Council for Science and Technology (HS1675). TFV and FTC
were measured in Nigerian HIV-positive nursing mothers (n = 6) re-
cruited from Bishop Murray Medical Centre, Benue State, Nigeria, a
cohort which has been reported in detail elsewhere [18]. Ethical ap-
proval was obtained from the National Health Research and Ethics
Table 1
Inter-day precision and accuracy for DBS and DBMS assays for TFV, 3TC and FTC.
Tenofovir (TFV) Lamivudine (3TC) Emtricitabine (FTC)
Nominal value (ng/ml) mean Precision (CV%) accuracy (%) mean Precision (CV%) accuracy (%) mean Precision (CV%) accuracy (%)
DBS (Inter-assay)
16.6 (LLOQ) 16.6 9.36 −0.09 17.5 6.94 5.48 17.1 5.16 2.69
40 (LQC) 42.2 9.04 5.61 38.1 5.82 −4.83 40.0 5.69 −0.053
400 (MQC) 430.2 8.36 7.56 391.6 4.55 −2.093 394.5 3.68 −1.38
4000 (HQC) 4031.8 7.64 0.79 3753.8 7.76 −6.15 4046.9 5.66 1.17
DBS (Intra-assay)
16.6 (LLOQ) 16.2 11.2 −2.52 17.3 6.13 4.23 17.0 4.12 2.21
40 (LQC) 41.7 10.9 4.32 38.2 5.77 −4.39 39.7 5.71 −0.88
400 (MQC) 424.9 9.79 6.23 398.1 4.54 −0.49 395.6 3.52 −1.09
4000 (HQC) 4188.5 5.13 4.71 3798.2 8.09 −5.04 4080.9 5.65 2.02
Tenofovir (TFV) Lamivudine (3TC) Emtricitabine (FTC)
mean precision accuracy (%) mean precision accuracy (%) mean precision accuracy (%)
DMBS (Inter-assay)
TFV 3TC/FTC
4.2 (LLOQ) 16.6 (LLOQ) 4.39 16.8 4.41 16.02 11.43 −3.49 16.39 7.22 −1.23
10 (LQC) 40 (LQC) 10.6 18.5 6.43 40.66 17.69 1.64 39.37 12.95 −1.58
40 (MQC) 400 (MQC) 37.23 7.21 −6.93 376.5 4.44 −5.87 372.7 4.66 −6.81
500 (HQC) 4000 (HQC) 512.5 6.43 −6.83 4306.9 4.96 7.67 4257.8 4.10 6.44
DBMS (intra-assay)
TFV 3TC/FTC
4.2 (LLOQ) 16.6 (LLOQ) 4.14 12.1 −1.55 16.3 14.8 −1.50 17.5 3.08 5.65
10 (LQC) 40 (LQC) 10.6 9.34 6.13 40.4 7.62 0.95 36.4 8.26 −9.04
40 (MQC) 400 (MQC) 36.7 5.09 −8.28 386.2 2.86 −3.44 376.5 5.01 −5.88
500 (HQC) 4000 (HQC) 503.9 7.67 −8.38 4331.3 6.52 8.28 4228.8 4.86 5.72
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Committee (NHREC), Abuja and Obafemi Awolowo University
Teaching Hospitals (OAUTHC) Ethics and Research Committee, Ife-Ife,
Nigeria.
Paired maternal DBS (mDBS) and DBMS were collected prior to and
at 1, 2, 4, 6 and 8 h (3TC, Ugandan cohort), or 0.5, 1, 2, 4, 8 and 12 h
(Nigerian cohort) following an observed dose of the drug, taken after a
standard breakfast. Ugandan subjects on TFV-containing regimens had
trough PK concentrations measured at 12, 16 and 20 h post dosing (not
observed) to enable comparison between mDBS and plasma. In Uganda,
an intravenous cannula was inserted and 2 mL venous whole blood
taken at these time points into EDTA tubes. mDBS were prepared by
accurately pipetting 50 μL blood onto the Whatman 903 Protein Saver
card; plasma was harvested from the remaining sample and stored at
−80 °C until shipment, which enable direct comparison of concentra-
tions obtained from mDBS with plasma. In Nigeria, mDBS samples were
collected by direct spotting onto the card, following ﬁnger-prick with a
sterile lancet. Within 2 min of DBS collection, about 5 mL of BM was
manually expressed by the mother and 30 μL aliquots were pipetted
onto each circle on the Whatman 903 Protein Saver card. DBS samples
were collected from infants (iDBS) at 2 h and 8 h post maternal dosing,
after sterile skin cleaning and heel prick using a 2 mm safety lancet (BD,
Oxford, Oxfordshire, UK). All samples were stored locally at −80 °C,
transported to the Department of Molecular and Clinical Pharmacology,
University of Liverpool, UK for analysis on dry ice and then kept at
−80 °C. This was because the results from Section 2.7 on long-term
stability at room temperature were not yet available.
In both cohorts, all infants were breastfed on demand to reﬂect real-
life situations.
The plasma samples from Ugandan women were processed as fol-
lows. To 100 μL of plasma sample 20 μL of internal standard mixture
3TC-IS (2.5 μg/mL) and FTC-IS (2.5 μg/mL) were added. 400 μL of
acetonitrile was added to precipitate the proteins followed by cen-
trifugation at 4000 rpm for 10 min 300 μL of the above supernatant was
removed and evoparated to dryness under nitrogen steam. The dried
residue was dissolved in 100 μL of water: acetonitrile (99:1 v/v) and
transferred into auto sampler vials. The samples were analysed on a
validated LC–MS/MS method [19].
2.10. Data analysis
Non-compartmental analysis of pharmacokinetic data was under-
taken using WinNonLin (Phoenix, version 6.1; Pharsight Corp.,
Table 2
Recovery and matrix eﬀect for DBS and DBMS assays for 3TC, FTC and TFV.
Drug Level %ME(B/A*100)
(SD)
%PE(C/A*100)
(SD)
%RE (SD) (C/
B*100)
DBS
TFV LQC 107.3 (10.21) 61.0 (6.03) 56.9 (2.59)
MQC 105.1 (3.76) 66.4 (3.02) 63.1 (2.43)
HQC 101.9 (2.55) 69.8 (1.39) 68.4 (1.71)
Mean
(%CV)
104.8 (2.57) 65.7 (6.70) 62.8 (9.20)
3TC LQC 106.33 (4.30) 73.09 (7.03) 94.6 (8.11)
MQC 114.52 (5.35) 90.22 (1.78) 98.7 (2.78)
HQC 119.96 (6.96) 94.84 (3.79) 83.3 (5.59)
Mean
(%CV)
113.6 (5.54) 86.05 (4.20) 92.2 (8.68)
FTC LQC 119.4 (8.31) 56.6 (3.30) 46.9 (0.64)
MQC 113.4 (4.16) 63.3 (2.93) 55.8 (2.49)
HQC 100.5 (2.82) 64.8(2.17) 64.2 (1.41)
Mean
(%CV)
111.3 (8.45) 61.6 (7.11) 55.7 (15.0)
DBMS
TFV LQC 101.3 (4.97) 59.46 (10.0) 53.1 (5.89)
MQC 113.1 (5.79) 44.89 (3.79) 40.3 (3.30)
HQC 108.1 (4.97) 56.52 (4.72) 52.3 (3.87)
Mean
(%CV)
107.5 (5.51) 53.6 (14.4) 48.6 (14.7)
3TC LQC 97.5(7.13) 57.9 (1.48) 59.6 (6.21)
MQC 98.5 (8.04) 60.3 (4.76) 61.2 (3.64)
HQC 99.3(6.89) 75.2 (3.55) 77.6 (7.63)
Mean
(%CV)
98.5 (0.93) 64.5 (14.5) 66.1 (14.9)
FTC LQC 88.1 (4.08) 71.9 (7.58) 80.2 (6.35)
MQC 84.7 (7.53) 54.5 (7.40) 67.2 (8.09)
HQC 79.1 (4.94) 68.3 (9.09) 86.4 (11.5)
Mean
(%CV)
83.9 (5.43) 64.9 (14.1) 77.9 (12.6)
A = Peak area of aqueous mobile phase solutions without matrix and without extraction;
B = Peak area of analyte spiked after extraction; C = Peak area of analyte spiked prior to
extraction; %ME =Matrix eﬀect expressed as the ratio of the mean peak area of the
analyte spiked after extraction (B) to the mean peak area of an equivalent concentration
of analyte in mobile phase (A) × 100; %RE = Extraction yield calculated as the ratio of
the mean peak area of the analyte spiked prior to extraction (C) to the mean peak area of
the analyte spiked after extraction (B) × 100; %PE = Process eﬃciency expressed as the
ratio of the mean peak area of the analyte spiked prior to extraction (C) to the mean peak
area of the same analyte in mobile phase (A) × 100; %CV coeﬃcient of variation
(standard deviation/mean × 100).
Table 3
Short and long term storage stability of DBS and DBMS (TFV, 3TF and FTC).
Tenofovir Lamivudine Emtricitabine
Storage condition Level DBS DBMS DBS DBMS DBS DBMS
Mean (%CV)
[% acuaracy]
Mean (%CV)
[% accuracy]
Mean (%CV)
[% accuracy]
Mean (%CV)
[% accuracy]
Mean (%CV)
[% accuracy]
Mean (%CV)
[% accuracy]
Autosampler stability of extracted samples (24 h at 4 °C) LQC 42.8 (7.7)
[107]
11.4 (7.8)
[114]
38.1 (7.0)
[95]
34.2 (5.4)
[86]
39.6 (8.6)
[99]
35.4 (5.5)
[89]
MQC 433 (4.3)
[108]
40.3 (9.3)
[101]
400.1 (1.9)
[100]
377.8 (3.9)
[94]
395 (4.1)
[99]
371.5 (4.9)
[93]
HQC 3720 (6.4)
[93]
554 (4.4)
[111]
3820 (7.6)
[96]
4177 (4.0)
[104]
2964 (5.4)
[74]
4314 (5.2)
[108]
Long-term stability of dried blood spots (6 months at 24 °C) LQC 41.7 (7.8)
[104]
63.1 (6.9)
[126]
44.7 (4.1)
[111]
MQC 420 (8.8)
[105]
433 (8.9)
[108]
336.2 (5.6)
[85]
HQC 4340 (6.2)
[108]
4418 (4.5)
[110]
3454.3 (12.1)
[86]
Long-term stability of dried milk spots (9 months at 24 °C) LQC 10.9 (11.7)
[109]
44.1 (6.1)
[110]
44.8 (3.1)
[112]
MQC 43.9 (11.9)
[110]
344 (3.9)
[86]
411 (1.7)
103]
HQC 466 (7.4)
[104]
3655 (5.4)
[91]
4207 (1.7)
[105]
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Mountain View, CA).
To evaluate the agreement between mDBS and plasma concentra-
tions of the drugs, the paired mDBS and plasma samples from Ugandan
mothers were correlated using linear regression. This andBland Altman
analysis was undertaken using GraphPad Prism (version 5.00 for
Windows, GraphPad Software, San Diego California USA, www.
graphpad.com). Ratios between concentrations measured in breast
milk and maternal dried blood samples were calculated arithmetically
and are expressed as DBMS:mDBS ratios.
3. Results
3.1. LC–MS/MS conditions
The transitions (collision energy) were 230.1→ 112.1m/z (14) for
3TC, 248.0→ 130.1m/z (15) for FTC, 288.1→ 176.1m/z (25) for TFV,
233.0→ 115.1m/z (15) for 3TC-IS and 251.1→ 133.1m/z for FTC-IS
(13). The scan width was set at 0.01 m/z and the dwell time at 0.01 s.
Representative chromatograms are shown in Fig. 1, with a retention
times of 2.20 min for 3TC, 2.27 min for FTC, 1.73 for TFV, 2.20 min for
3TC-IS and 2.27 min for FTC-IS. FTC-IS was used as internal standard
for quantitation of TFV.
3.2. Calibration curves, accuracy and precision (Table 1)
The method was quadratic with weighing factor (1/x2) in the range
of 16.6–5000 ng/mL for all analytes except TFV DBMS which was linear
with weighing factor (1/x) in the range of 4.2–1250 ng/mL, with intra
and inter-day accuracy and precision within the acceptance criteria as
per FDA and EMA guidelines (Table 1). The mean regression coeﬃcient
was> 0.99 in both DBS and DBMS.
3.3. Recovery, matrix eﬀect and dilution integrity (Table 2)
The mean (±CV%) percentage (%) recovery (RE), process eﬃ-
ciency (PE) and contribution of the sample matrix (ME) are summarized
in Table 2. The mean RE (%CV) of 3TC, FTC and TFV from DBS were
92.2% (8.68), 55.7% (15.0) and 62.8% (9.20), respectively, and from
DBMS were 66.1% (14.9), 77.9 (12.6) and 48.6% (14.4), respectively.
The percentage ME ranged between 104 and 113% (%CV 2.5-10.2) for
the analytes in DBS, and from 83 to 107% (%CV 1–8) for DBMS, re-
spectively.
3.4. Dilution integrity
After 2× and 4× dilutions, the mean (%CV) back calculated con-
centrations for 9000 ng/mL DBS samples were within 92.4% (3.36) and
98.7% (9.13), 104.6% (3.94) and 114.6% (6.6) and 88.3% (3.36) and
94.1% (7.83) of their nominal values for 3TC, FTC and TFV, respec-
tively.
3.5. Stability and re-injection reproducibility
Table 3 shows the short-term stability of 3TC, FTC and TFV in
processed samples, and the long term stability in DBS and DBMS when
stored at ambient temperature. Following re-injection of accepted
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Fig. 2. Correlation and Bland-Altman comparison between 3TC and TFV concentrations in mDBS and plasma.
The dotted lines indicate the mean diﬀerence and the 95% limits of agreement (mean diﬀerence ± standard deviation)
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validation batches of DBS and DBMS, stored in the autosampler for 24 h
at 4 °C, all assay validation parameters were within acceptable limits,
demonstrating re-injection reproducibility.
3.6. Eﬀect of haematocrit
The diluted whole blood demonstrated HCT percentages of 55, 44,
31, 25, 16 and 0%. The eﬀect of haematocrit in blood was negligible on
the quantitation of 3TC, FTC and TFV concentrations in DBS until HCT
fell to 8%, reﬂecting conditions of severe anaemia (Supplementary
Figure A). In the patient population, the plasma:mDBS ratio for 3TC and
TFV remained constant within haematocrit range 30–50%
(Supplementary Figure B). All participants at both study sites had
haematocrit within this range.
3.7. Correction for plasma
Plasma and mDBS concentrations of 3TC and TFV showed a strong
positive correlation (R2 = 0.92 and 0.70, respectively). Using a cor-
rection factor derived from the average plasma:mDBS ratio (0.88 for
3TC and 1.57 for TFV), Bland-Altman analysis indicated good agree-
ment between the two methods (Fig. 2).
3.8. Clinical application
The six Ugandan mothers had a mean (range) age of 30 (24–41)
years and a body weight of 54 (47–82) kg. Infants were aged 106
(83–146) days and weighed 5.88 (5.4–6.2) kg. In mDBS, 3TC reached a
median (IQR) Cmax of 993 (770–1598) at a Tmax of 4 (2.5–5.5) h. The
mDBS AUC0-8 was 4683 (4165–6057) ng h/mL. In BM, the Cmax of 994
(958–1274) ng/mL was reached at a Tmax of 3 (2–4) h, and the AUC0-8
was 6050 (5217–6417) ng h/mL. The DBMS:mDBS ratio of AUC0-8 was
1.31 (0.98–1.51). Two infants had detectable iDBS levels, of 13.2 and
15.6 ng/mL.
The six Nigerian mothers had a mean age of 28 years (23–30) and
weighed 58 (52–63) kg. Infants were of mean age 164 (101–219) days
and weighed 7.5 (6–10) kg. In mDBS, TFV reached a Cmax of 217
(181–278) ng/mL at a Tmax of 2 (1.25–2) h, giving an AUC0-12 of 1559
(930–1915) ng h/mL. In the BM, a Cmax of 5.9 (5.5–8.0) ng/mL was
reached at a Tmax of 3 (1–7) h, with an AUC0-12 of 56 (45–80) ng h/mL.
The DBMS:mDBS ratio of AUC0-8 was 0.04 (0.025–0.058), and no in-
fants had detectable iDBS levels. FTC in mDBS reached a Cmax of 547
(467–719) at a Tmax of 2 (1.25–3.5) h. The AUC0-12 was 3312
(2259–4312) ng h/mL. In BM, FTC reached a Cmax of 872 (696–1063) at
a Tmax of 3 (2–4) h, and an AUC0-12 of 4853 (4124–6691) ng h/mL. The
DBMS:mDBS ratio of AUC0-12 was 1.77 (1.62–2.24). One infant had
detectable FTC at 17.5 ng/mL. These data are presented in Fig. 3.
4. Discussion
International guidelines now recommend that HIV positive women
who are pregnant and breastfeeding receive triple antiretroviral
therapy with EFV, TFV and 3TC or FTC [1]. To enable the further in-
vestigation of the pharmacokinetics of these drugs in this population,
we have developed and validated a straightforward, accurate and pre-
cise method for the quantitation of 3TC, FTC and TFV in DBS and
DMBS. Whilst recent work has described a DBS assay for TFV/FTC
[20,21], the method for 3TC quantitation in human DBS has not been
reported, and DBMS assays for these NRTIs have not previously been
developed. Furthermore, we report full pharmacokinetic proﬁles of
plasma and BM FTC and TFV from HIV-positive breastfeeding mothers
together with matched infant data.
Plasma processing requires relatively large volumes of blood, access
to trained laboratory personnel and equipment for centrifugation and
storage and speciﬁc shipping requirements which are cumbersome and
expensive. DBS sampling therefore oﬀers advantages of ease of collec-
tion, lower blood volumes, and simpler short-term storage and trans-
port of specimens. This makes the technique ideal for ﬁeld studies of
vulnerable populations (such as pregnant women and breastfeeding
infants). Whilst volumetric absorptive microsampling methodologies
are emerging as an alternative method for accurate quantitation of
drugs [22], these have not yet been widely used in low-resource set-
tings. The method we report is immediately available and applicable for
ongoing ﬁeld studies.
In pilot cohorts of breastfeeding mother-infant pairs from Uganda
and Nigeria, we have shown that both 3TC and FTC penetrate into the
breast, with peak concentrations (described by both Cmax and AUC)
greater than those reached in maternal plasma. In two out of six
Ugandan infants, 3TC was measurable, and in one out of six Nigerian
infants, FTC could be quantiﬁed. On a programmatic level, this may
have important implications. Whereas low levels of these drugs were
initially thought to be of trivial clinical signiﬁcance due to the level
being lower than the reported inhibitory concentrations of the drug
[23], more recent work indicated that the breastfed infants of HIV-
positive mothers who require HIV despite maternal ART have high rates
of multi-class drug resistance [4,24] which is thought to relate to long
term exposure to low levels of the drugs. Tenofovir has previously been
measured in BM in cross-sectional studies [8–10] and we now report
low but detectable concentrations in the BM of all six Nigerian women
Fig. 3. A Blood, BM and Infant 3TC concentrations at 0–8 h post 150 mg dose in 6
Ugandan mother-infant pairs; B Blood, BM and Infant FTC concentrations at 0–12 h post
300 mg dose in 6 Nigerian mother-infant pairs; C Blood, BM and Infant FTC concentra-
tions at 0–12 h post 300 mg dose in 6 Nigerian mother-infant pairs.
Data are presented as median (IQR)
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included in this pilot work. Although infant levels were not measurable,
the clinical implications of low concentrations of tenofovir in the breast
milk are not known.
Further evaluation of the pharmacokinetics of these drugs as WHO
policy is implemented is therefore a priority to ensure the safest use of
these drugs. Furthermore, clinical covariates which may impact on drug
levels are often exclusion criteria from clinical and intensive pharma-
cokinetic studies; utilisation of sparse PK sampling to investigate the
full spectrum of these patients will be informative, and we have now
developed the necessary assay to facilitate such studies.
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